Healthcare -
Biotechnology - NASDAQ - US
$ 13.89
0.364 %
$ 355 M
Market Cap
-22.26
P/E
1. INTRINSIC VALUE
Balance Sheet
Benitec Biopharma Inc.
| Current Assets | 51.7 M |
| Cash & Short-Term Investments | 50.9 M |
| Receivables | 229 K |
| Other Current Assets | 579 K |
| Non-Current Assets | 536 K |
| Long-Term Investments | 0 |
| PP&E | 449 K |
| Other Non-Current Assets | 87 K |
| Current Liabilities | 4.92 M |
| Accounts Payable | 1.35 M |
| Short-Term Debt | 284 K |
| Other Current Liabilities | 3.29 M |
| Non-Current Liabilities | 38 K |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 38 K |
EFFICIENCY
Earnings Waterfall
Benitec Biopharma Inc.
| Revenue | 216 K |
| Cost Of Revenue | 108 K |
| Gross Profit | 108 K |
| Operating Expenses | 22.4 M |
| Operating Income | -22.5 M |
| Other Expenses | -739 K |
| Net Income | -21.8 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Benitec Biopharma Inc.
| Net Income | -21.8 M |
| Depreciation & Amortization | 343 K |
| Capital Expenditures | -179 K |
| Stock-Based Compensation | 830 K |
| Change in Working Capital | 1.17 M |
| Others | 234 K |
| Free Cash Flow | -19.6 M |
Wall Street Analysts Price Targets
Benitec Biopharma Inc.
Wall Street analysts predict an average 1-year price target for BNTC of $19.2 , with forecasts ranging from
a
low of
$13 to a high of $30 .
BNTC Lowest Price Target
Wall Street Target
13 USD
-6.41%
BNTC Average Price Target
Wall Street Target
19.2 USD
38.59%
BNTC Highest Price Target
Wall Street Target
30 USD
115.98%
4. DIVIDEND
ANALYSIS
0.00%
DIVIDEND YIELD
0.765 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Benitec Biopharma Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
11.9 M USD 1
0-3 MONTHS
1.35 M USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Benitec Biopharma: An Under-The-Radar And Undervalued Gene Therapy Developer
We initiate a Buy rating for Benitec Biopharma due to promising early data from BB 301 for OPMD and a cash runway into mid-2027. BB 301 shows potential for meaningful improvements in swallowing function, with significant commercial opportunities and an undervalued stock price reflecting high-dose cohort data. Financially, Benitec has no revenue, rising operating expenses, and a cash balance of $78.3 million, providing a runway into mid-2027, though burn rate may increase.
seekingalpha.com
- 2 weeks ago
Insiders Are Loving These 5 Tech and Biotech Stocks
After struggling through a rough patch, the biotech industry seems to be staging a comeback.
247wallst.com
- 1 month ago
Benitec Biopharma Inc. Announces Pricing of $30 Million Common Stock Offering
HAYWARD, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference (“ddRNAi”) “Silence and Replace” platform, today announced the pricing of its underwritten offering of 1,443,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and a concurrent registered direct offering of 900,000 shares of its common stock with long-term investor Suvretta Capital.
globenewswire.com
- 1 month ago
Wall Street Analysts Predict a 127.26% Upside in Benitec Biopharma (BNTC): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 127.3% in Benitec Biopharma (BNTC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
zacks.com
- 2 months ago
Benitec Biopharma (BNTC) is on the Move, Here's Why the Trend Could be Sustainable
Benitec Biopharma (BNTC) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
zacks.com
- 2 months ago
Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update
-Fifth Subject in BB-301 Phase 1b/2a Clinical Treatment Study safely treated in February 2025- -Interim clinical study update to be presented in late-breaking oral presentation at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference on March 19, 2025- HAYWARD, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its second fiscal quarter ended December 31, 2024.
globenewswire.com
- 2 months ago
Why You Shouldn't Bet Against Benitec Biopharma (BNTC) Stock
Benitec Biopharma (BNTC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
zacks.com
- 3 months ago
Recent Price Trend in Benitec Biopharma (BNTC) is Your Friend, Here's Why
Benitec Biopharma (BNTC) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
zacks.com
- 4 months ago
Wall Street Analysts See an 113.71% Upside in Benitec Biopharma (BNTC): Can the Stock Really Move This High?
The mean of analysts' price targets for Benitec Biopharma (BNTC) points to an 113.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
zacks.com
- 4 months ago
Benitec Biopharma (BNTC) Is a Great Choice for 'Trend' Investors, Here's Why
Benitec Biopharma (BNTC) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
zacks.com
- 4 months ago
Benitec Biopharma to Participate in Upcoming Investor Conferences in December
HAYWARD, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, today announced that its management team will participate in the following upcoming investor conferences.
globenewswire.com
- 5 months ago
Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update
-Positive 270-day Interim Clinical Study Data for the First Subject and Positive 180-day Interim Clinical Study Data for the Second Subject Treated with the Low-Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study Reported in October as a Late-Breaking Oral Presentation at the 29 th Annual Congress of the World Muscle Society-
globenewswire.com
- 5 months ago
8. Profile
Summary
Benitec Biopharma Inc. BNTC
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 355 M
Dividend Yield
0.00%
Description
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
Contact
3940 Trust Way, Hayward, CA, 94545
https://benitec.com
IPO
Date
June 24, 2014
Employees
16
Officers
Ms. Sophie Mukadam
Chief Operating Officer
Dr. Claudia Kloth Ph.D.
Senior Vice President of Manufacturing
Dr. Jerel A. Banks M.D., Ph.D.
Executive Chairman & Chief Executive Officer
Ms. Megan Joan Boston B.Com., C.A.
Chief Financial Officer & Director
Dr. Michael Graham
Head of Discovery & Founding Scientist